MARLBOROUGH, Mass.,
May 19, 2016 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) today announced
the launch of the Precision Montage™ MRI Spinal Cord
Stimulator (SCS) System after receiving approval from the U.S. Food
and Drug Administration. The Precision Montage System offers
customized relief to patients with chronic pain while also enabling
safe access to full body magnetic resonance imaging (MRI) in a 1.5
Tesla environment when conditions of use are met. Boston Scientific
is introducing the system at the 8th World Congress of the World
Institute of Pain in New York City
on May 20-23, 2016.
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7839551-boston-scientific-precision-montage-mri/
More than 100 million Americans suffer from chronic pain, which
can have a devastating impact on quality of life. Patients with
pain sometimes experience a fluctuation in location, type and
intensity of pain throughout the day or over time. The Precision
Montage MRI SCS System allows patients to undergo a full-body MRI
while benefiting from the pain relief of MultiWave™ Technology.
MultiWave Technology enables delivery of multiple waveforms,
including burst and higher rates, intended to help respond to
changes in pain over time. In an analysis of registry
information from 800 patients, it was determined that 72 percent
used multiple waveforms to customize their therapy and optimize
pain relief.
The new SCS system also expands the suite of Boston Scientific
products that leverage the Illumina 3D™ algorithm, a
three-dimensional anatomy-driven computer model designed for simple
point-and-click pain targeting to support physicians in treating
chronic pain. In addition to the new Precision Montage MRI SCS
System, the portfolio includes the Precision Spectra™ System, which
is designed to provide broad coverage for pain with 32 contacts,
and the Precision Novi™ System, the smallest high-capacity
non-rechargeable device. The LUMINA clinical study has demonstrated
70 percent greater low-back pain relief with the SCS system in the
Illumina 3D family, which was maintained out to
24-months.1
"The Boston Scientific Illumina 3D portfolio allows me to tailor
therapy for each patient consistently and effectively," said
Salim Hayek, M.D., Ph.D., program
director, Anesthesiology Pain Medicine, University Hospital,
Cleveland, Ohio. "With the
approval of the Precision Montage MRI SCS System, more of my
patients can benefit from this powerful technology since they can
now have access to future MRI scan needs."
"The Precision Montage MRI SCS System is a key addition to our
Illumina 3D portfolio, offering patients more choices to manage and
personalize their therapy," said Maulik
Nanavaty, senior vice president and president,
Neuromodulation, Boston Scientific. "This important advancement
underscores our commitment to meet the individual needs of chronic
pain patients."
For more product and important safety information, please visit
the Precision Montage MRI SCS System product page.
Boston Scientific
Boston Scientific transforms lives
through innovative medical solutions that improve the health of
patients around the world. As a global medical technology leader
for more than 35 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect,"
"project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding regulatory approvals, new product
launches, and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A – Risk
Factors in our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, which we may update in Part
II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we
have filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements. This
cautionary statement is applicable to all forward-looking
statements contained in this document.
1Boston Scientific LUMINA data presented
at the 19th annual meeting of the North American Neuromodulation
Society
CONTACTS:
Catherine
Brady
508-683-4797(office)
Media
Relations
Boston Scientific
Corporation
catherine.brady@bsci.com
Investors: Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-receives-us-fda-approval-for-precision-montage-mri-spinal-cord-stimulator-system-300271501.html
SOURCE Boston Scientific Corporation